IL-2R

IL-2R Full Name

interleukin-2 receptor

IL-2R Introduction

Interleukin-2 receptor (IL-2R) is a key immune signaling complex that plays a central role in regulating T-cell activation and immune homeostasis. It is a heterotrimeric receptor composed of three subunits—IL-2Rα (CD25), IL-2Rβ (CD122), and the common γ chain (γc, CD132)—that together mediate cellular responses to the cytokine interleukin-2 (IL-2). In resting immune cells, only the β and γ subunits are typically expressed, forming an intermediate-affinity receptor, while the high-affinity IL-2Rαβγ complex is rapidly assembled upon immune activation. This dynamic receptor assembly enables immune cells to precisely sense IL-2 levels and regulate processes such as naïve T-cell activation, clonal expansion, and differentiation into effector and memory T cells. For researchers and drug developers working in immunology, understanding IL-2R signaling is critical because dysregulated IL-2 pathways can profoundly affect immune balance, influencing both protective immunity and immune-mediated pathology.

Functionally, IL-2R is a pivotal mediator of downstream intracellular signaling pathways that control lymphocyte proliferation and survival. When IL-2 binds to IL-2R, conformational changes in the IL-2Rβ and γc subunits trigger activation of the JAK/STAT pathway, particularly JAK1/JAK3 and STAT5, which subsequently drive transcriptional programs responsible for T-cell growth and differentiation. Recent structural biology research has provided detailed insights into how IL-2 induces receptor activation at the molecular level, revealing the conformational rearrangements that stabilize the IL-2Rβγ signaling complex. These mechanistic insights have enabled the engineering of IL-2 variants with altered receptor selectivity. For example, engineered IL-2 molecules such as bempegaldesleukin (NKTR-214) and nemvaleukin are designed to preferentially activate the IL-2Rβγ dimer while minimizing interaction with IL-2Rα. This strategy selectively stimulates cytotoxic effector T cells and natural killer cells while reducing activation of regulatory T cells, thereby improving the therapeutic window for immunotherapy.

Growing clinical and translational evidence highlights IL-2R as a promising therapeutic target across a range of diseases, particularly cancer and autoimmune disorders. In oncology, elevated expression of IL-2R subunits—especially CD25—has been observed in multiple tumor microenvironments and is often associated with immune cell infiltration and patient prognosis. Studies in osteosarcoma and other solid tumors have shown that higher IL-2R expression correlates with increased CD8+ T-cell infiltration, suggesting that IL-2R signaling may influence antitumor immunity and responsiveness to cytokine-based immunotherapies. At the same time, dysregulated IL-2R signaling has also been implicated in autoimmune diseases such as multiple sclerosis, where increased CD25 expression in infiltrating immune cells contributes to inflammatory pathology. Experimental studies demonstrate that blocking IL-2Rα can reduce disease severity in autoimmune models, indicating its potential as a therapeutic intervention point. Collectively, these findings position IL-2R not only as a classical cytokine receptor but also as a central node in modern immunotherapy strategies, offering opportunities for precision immune modulation in both cancer treatment and autoimmune disease management.

Alternate Names for IL-2R

IL2R; interleukin-2 receptor; IL-2R

• 1.Hernandez R, et al.; Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat Rev Immunol. 2022, 22(10):614-628.
  2.Smadja J, et al.; Rational modification, synthesis and biological evaluation of N-substituted phthalazinone derivatives designed to target interleukine-15 protein. Bioorg Med Chem. 2021, 39:116161.